Every lot is tried & tested in a relevant biological assay.
- Zhou, C. et al. (2007) Mol. Pharmacol. 72, 976.
- Alomone Labs Quin-C7 partially inhibits FPR2 activation in HL-60 cells.Non-differentiated HL-60 human acute promyelocytic leukemia cells were loaded with Fluo-3 AM. Changes in intracellular Ca2+ were detected as changes in Fluo-3 emission following stimulation. Normalized fluorescence is shown before and after application (arrow) of 10 nM FPR agonist WKYMVm (#GPW-105) in absence (top trace) or in presence of 100 µM Quin-C7 (#Q-155) (middle trace), compared to baseline (bottom trace).
Quin-C7 is a synthetic quinazolinone derivative that acts as a nonpeptide antagonist of human formyl peptide receptor like 1 (FPRL1, FPR2)1. Quin-C7 can partially displace [(125)I]Trp-Lys-Tyr-Met-Val-d-Met-NH(2) (WKYMVm) binding to FPRL1 receptor1.
Quin-C7 (#Q-155) is a highly pure, synthetic, and biologically active compound.